The Latest Cardiac and Vascular News
heart-1 Clinical Trial of VERVE-101 Ongoing in New Zealand and UK; Data from Dose Escalation Cohorts Expected in the Second Half of 2023 VERVE-201 Progressing Through Preclinical Development with Clinical Initiation Anticipated in 2024 Well-Capitalized with $554.8 Million Supporting Runway into the Second Half of 2025 BOSTON, March 02, 2023 […]
McDermott + Bull Partner Ken Dropiewski interviews Gilde Healthcare General Partner Geoff Pardo in his series, Investor Insights in Life Sciences + MedTech. In the conversations below, Ken and Geoff discuss what venture in MedTech will look like in 2023, what Gilde Healthcare looks for in new investment opportunities, and more.
— System Leverages Next Generation DeepOCT™ Technology and Near Infrared Spectroscopy to Optimize Coronary Stent Placement in the Cardiac Catheterization Lab — — First-in-Human Cases Completed with HyperVue System — BEDFORD, Mass.–(BUSINESS WIRE)–SpectraWAVE, Inc., a medical imaging company focused on improving the treatment and outcomes for patients with coronary artery […]
Phase 1 clinical trial (CHIHUAHUA) demonstrates that single dose of second-generation DSR product (DSR 2.0) is safe and well-tolerated, and indicates a compelling dosing profile On track to file INDi application to US FDA in Q1 2023 Start of MOJAVE, a US multi-center randomized controlled Phase 1/2a clinical trial of […]
Combined Data From FOURIER and FOURIER-OLE Studies Show Earlier, Longer Use of Repatha Reduces Total CV Events Analysis From Phase 2 OCEAN(a)-DOSE Study Shows Olpasiran Markedly Reduced Lp(a) Concentration Irrespective of Baseline Level Amgen Convenes First LDL-C Action Summit to Help Improve State of Cardiovascular Disease Care in the U.S. […]
The six-month EXCITE-HCM study of 70 patients will study the effects of exercise on electrical activity and blood flow using Vivalink’s medical wearable ECG sensor and cloud data services. CAMPBELL, Calif., March 1, 2023 /PRNewswire/ — UC San Francisco (UCSF) is conducting a six-month clinical trial on hypertrophic cardiomyopathy (HCM) using Vivalink‘s Biometrics Data Platform. […]
Fully interoperable smart imaging systems and informatics solutions connect teams in radiology, oncology, cardiology and pathology to enhance clinical confidence and advance precision in diagnosis and treatment Vienna, Austria and Amsterdam, the Netherlands – Royal Philips (NYSE: PHG, AEX: PHIA), a global leader in health technology, today announced its radiology portfolio of […]
Full year 2022 total revenues of $250.3 million, compared to $83.8 million in 2021 CAPLYTA fourth quarter 2022 net product sales grew to $87.4 million, a 243% increase over the same period in 2021 and a 22% sequential increase over the third quarter 2022 Full year 2022 CAPLYTA net product sales […]
— Company Delivers Positive Free Cash Flow in Fourth Quarter 2022 Following U.S. Revenue Stabilization — — Previously Announced Cost Savings Program On-Track to Exceed $100 Million Target — — European, International Strategies Advancing At-Pace with Significant Progress Throughout 2022, and Strong Position for 2023 — — Company to Host […]
Complete Response Letter States that GALACTIC-HF Alone Does not Establish Substantial Evidence of Effectiveness Sufficient for Approval Company Expects to Request Meeting with FDA to Discuss Potential Next Steps Cytokinetics to Host Conference Call and Webcast on March 1, 2023 at 8:30 am Eastern Time SOUTH SAN FRANCISCO, Calif., Feb. 28, […]
